Allarity Therapeutics Files 8-K
Ticker: ALLR · Form: 8-K · Filed: Sep 17, 2024 · CIK: 1860657
Sentiment: neutral
Topics: disclosure, corporate-event
TL;DR
Allarity Therapeutics filed an 8-K on 9/17 for an event on 9/16. Standard disclosure.
AI Summary
Allarity Therapeutics, Inc. filed an 8-K on September 17, 2024, reporting an event that occurred on September 16, 2024. The filing is categorized under Regulation FD Disclosure and Financial Statements and Exhibits. The company's principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA 02108.
Why It Matters
This 8-K filing indicates a significant event or update from Allarity Therapeutics, requiring immediate disclosure to the public under SEC regulations.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for a corporate event and does not inherently signal significant financial distress or operational risk.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- September 16, 2024 (date) — Date of earliest event reported
- September 17, 2024 (date) — Date of report
- 24 School Street, 2nd Floor, Boston, MA 02108 (location) — Principal executive offices
FAQ
What is the specific event being reported in this 8-K filing?
The filing does not specify the exact event, only that it occurred on September 16, 2024, and is categorized under Regulation FD Disclosure and Financial Statements and Exhibits.
When was this 8-K filing submitted to the SEC?
The filing was submitted on September 17, 2024.
What is the primary business of Allarity Therapeutics, Inc.?
Allarity Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Where are Allarity Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA 02108.
What is the Commission File Number for Allarity Therapeutics, Inc.?
The Commission File Number for Allarity Therapeutics, Inc. is 001-41160.
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-09-17 08:00:32
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea021470501-8k_allarity.htm (8-K) — 25KB
- ea021470501ex99-1_allarity.htm (EX-99.1) — 16KB
- image_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-079165.txt ( ) — 226KB
- allr-20240916.xsd (EX-101.SCH) — 3KB
- allr-20240916_lab.xml (EX-101.LAB) — 34KB
- allr-20240916_pre.xml (EX-101.PRE) — 22KB
- ea021470501-8k_allarity_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 16, 2024, Allarity Therapeutics, Inc. (the "Company"), issued a press release announcing that two patients enrolled in the Company's Phase 2 clinical trial of stenoparib for advanced, recurrent ovarian cancer have now exceeded one year on therapy. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated September 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer Dated: September 17, 2024